ArticleJournal of gastroenterology2020
Clinicopathological features and risk factors for lymph node metastasis in early-stage non-ampullary duodenal adenocarcinoma.
Article in Journal of gastroenterology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 23 citations in OpenAlex.
- Clinical practice guidelines for duodenal cancer 2025.Journal of gastroenterology · 2026Review
- Endoscopic Full-Thickness Resection for Gastrointestinal Subepithelial and Epithelial Neoplasia: Current Status, Indications, and Technical and Oncological Challenges-A Multispecialty Perspective.Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society · 2026Review
- Safety and Feasibility of Laparoscopic and Endoscopic Cooperative Surgery With Endoscopic Submucosal Dissection for Large Superficial Non-Ampullary Duodenal Epithelial Tumors.Annals of gastroenterological surgery · 2026Article
- Positive Lymph Nodes Independently Affect Long-Term Survival After Pancreaticoduodenectomy for Non-Ampullary Duodenal Adenocarcinoma: A Single-Center, Retrospective Analysis.Journal of clinical medicine · 2025Article
- Article
- Four cases of early stage poorly differentiated non-ampullary duodenal adenocarcinoma: a case report.Clinical journal of gastroenterology · 2025Article
- Risk factors for delayed bleeding after endoscopic resection of non-ampullary duodenal epithelial tumors and the effectiveness of complete mucosal closure in high-risk patients.Surgical endoscopy · 2025Article
- Endoscopic Resection for Superficial Non-Ampullary Duodenal Epithelial Tumors.Gut and liver · 2025Review
- Clinicopathological and Genetic Features in Superficial Nonampullary Duodenal Epithelial Tumors.Gastroenterology research and practice · 2025Article
- Pancreas-preserving partial duodenectomy for non-ampullary duodenal neoplasms: three case reports.Surgical case reports · 2022Article
- A novel diagnostic system for superficial nonampullary duodenal epithelial tumors sized ≤ 5 mm.Surgical endoscopy · 2022Article
- Review
- Article
- Sporadic non-ampullary duodenal adenoma with low-grade dysplasia: Natural history and clinical management.Endoscopy international open · 2022Article
- Prognostic Factors and Lymph Node Metastasis Patterns of Primary Duodenal Cancer.World journal of surgery · 2022Article
- Progress in gallbladder cancer with lymph node metastasis.Frontiers in oncology · 2022Review
- Endoscopic management of non-ampullary duodenal adenomas.Endoscopy international open · 2022Review
- Endoscopic Treatment for Superficial Nonampullary Duodenal Tumors.The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundManagement strategies for primary non-ampullary duodenal adenocarcinoma (NADAC) in early stage are not well established given its low incidence. This study aimed to elucidate clinicopathological features of early NADAC, including risk for lymph nodal metastasis (LNM).
methodsIn total, 166 patients with early NADAC underwent initial treatment at our institution between 2006 and 2019, of whom 153 had intramucosal (M-) and 13 had submucosal (SM-) NADAC. These endoscopic and pathological features were retrospectively analyzed. Risk factors for LNM were evaluated in 46 early NADAC patients who underwent surgery with lymph node dissection.
resultsCompared with M-NADAC, SM-NADAC was significantly more frequently located at the proximal side of the papilla, with mixed elevated and depressed macroscopic type, histologically poorly differentiated tumor and lymphovascular invasion (LVI) (85% vs. 47%, P = 0.009; 54% vs. 5%, P < 0.001; 23% vs. 0%, P < 0.001; and 46% vs. 0%, P < 0.001, respectively). The frequency of LNM was significantly higher in SM-NADAC than in M-NADAC (5/12, 42% vs. 0/34, 0%; P < 0.001). In SM-NADAC, the frequency of LNM was higher in poorly differentiated than in well to moderately differentiated tumors (3/3, 100% vs. 2/9, 22%) and higher in tumors with LVI than in those without LVI (3/5, 60% vs. 2/7, 29%). Regarding invasion depth, 2 of 4 patients with SM invasion (400 ≤ × < 500 µm) showed LNM. However, in this study, no patients developed very shallow SM invasion (0 < × < 400 µm).
conclusionsSM-NADAC showed high LNM risk. Surgical treatment with regional lymph node dissection is recommended as a treatment strategy for SM-NADAC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.